Key result
The HeartMate III LVAD demonstrated no mechanical failures, low hemolysis, and low thrombogenicity during six in vivo bovine studies lasting 27 to 59 days.
Population
In vitro models and 6 in vivo bovine models
Design
Preclinical
Follow-up
27 to 59 days (40, 27, 59, 42, 27, and 49-day studies)
Authors
Loading...
Supports progression to human trials of HeartMate III LVAD; leaves open long-term safety and efficacy in patients.
The HeartMate III LVAD demonstrated favorable hemodynamic performance, mechanical reliability, and hemocompatibility in preclinical in vitro and bovine models.
Bourque et al. (2001) studied this question. HeartMate III LVAD was evaluated on Mechanical failures, hemolysis, and thrombogenicity. The HeartMate III LVAD demonstrated no mechanical failures, low hemolysis, and low thrombogenicity during six in vivo bovine studies lasting 27 to 59 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: